Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Official title

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

Study identification

NCT ID

NCT07085767

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Olema Pharmaceuticals, Inc.

Industry

Enrollment

1,000 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Nov 3, 2025 (Actual)

Primary completion

Dec 2028 (Estimated)

Completion

Jan 2032 (Estimated)

Last update posted

Sep 23, 2026

2025 – 2032

United States locations

U.S. sites

62

U.S. states

29

U.S. cities

57

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 138 non-U.S. sites.